AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$UTHR

ROTHBLATT MARTINE A sold $4.7M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $493.46 ($477.70–$510.05, $4.69M total) across 24 trades on 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The disclosed sale adds a modest bearish data point for traders, but the pre‑arranged nature tempers significance.

02

Market read

Primary source filing; provides new information on insider activity that could influence short‑term trading decisions.

03

What to watch

The 10b5‑1 plan indicates no discretionary timing; the sale may not reflect insider outlook on the business.

Relevance 5/10Novelty 7/10Timing: post‑market 2026‑09‑02

Background

Form 4 filing reveals insider transaction details for United Therapeutics.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

CEO Martine Rothblatt sold $4.7M of United Therapeutics shares via a 10b5‑1 plan on 2026‑09‑02.

Expected impact

Potential modest dip in the near term as market digests the sale.

Evidence & confidence

C‑suite insider sale of ~9,500 shares (~0.3% of float) at $493 average price, disclosed in a Form 4, typically viewed as a bearish signal.

Market effects

Sector

May weigh on biotech/biopharma sector sentiment as insider sales are monitored.

Regional

Limited to U.S. markets where United Therapeutics trades.

Global

Minimal global impact beyond investors tracking the stock.

Counterpoint

What could challenge this read

The sale could be routine liquidity management under a pre‑arranged plan, not a negative signal.

Key entities

  • company
    United Therapeutics Corp

    Biopharma company listed on NASDAQ under ticker UTHR.

  • person
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics, reporting the insider sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 28
$UTHRMed

United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

finance.yahoo.com2 min
OCT 28
$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.

stocktitan.net2 min